{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6","upperLimit":"79","value":"45.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"The visual analog scale ranges from 0-100. 0 is labeled as \"no nausea\" and 100 is labeled as \"nausea as bad as it could be\" A score of \\< 25 is considered to indicate no significant nausea. All patients discontinued trial after only one cisplatin infusion.","dispersionType":"Full Range","groups":[{"description":"Patients receive cisplatin IV on day 1. Treatment repeats every 21 days for up to 3 courses. Patients undergo radiotherapy once daily 5 days a week for up to 7 weeks.\n\nPatients receive fosaprepitant dimeglumine IV, palonosetron hydrochloride IV, and dexamethasone IV on day 1.Patients receive oral dexamethasone on days 2-4. Patients with no emesis or need for rescue anti-emetics in the first 120 hours after cisplatin infusion continue to receive the anti-emetic regimen as above with the second and third courses of cisplatin.\n\nPatients complete an emesis diary daily for 5 days after each cisplatin infusion. Patients also complete a Functional Living Index-Emesis Questionnaire on day 8 after each cisplatin infusion.\n\nfosaprepitant dimeglumine: Given IV\n\ncisplatin: Given IV\n\npalonosetron hydrochloride: Given IV\n\ndexamethasone: Given IV and orally\n\nFunctional Living Index-Emesis Questionnaire: Ancillary studies\n\nEmesis Diary: Ancillary studies\n\nRadiotherapy: Undergo r","id":"OG000","title":"Arm I"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"120 hours following cisplatin infusion","title":"Control of Nausea for 120 Hours Following Each Cisplatin Infusion for Multiple Cycles of Therapy as Measured by the Visual Analog Scale","type":"SECONDARY","unitOfMeasure":"millimeters"}